OBI Pharma
OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (including Globo H, SSEA-3, and SSEA-4), AKR1C3, and other promising targets. The company's novel first-in-class immuno-oncology portfolio against Globo H includes: Adagloxad Simolenin (formerly OBI-822) and OBI 833, a Globo H active immunotherapy vaccine; OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC). The company's novel first-in-class AKR1C3 targeted therapy is OBI-3424 (small-molecule prodrug) that selectively releases a potent DNA alkylating agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme.
About OBI Pharma
Founded
2002Estimated Revenue
$10M-$50MEmployees
51-250Category
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
BiotechnologyLocation
City
San DiegoState
CaliforniaCountry
United StatesTech Stack (67)
Programming Languages And Frameworks
Platform And Storage
Communications
Devops And Development
IT Security
Computer Networks
Productivity And Operations
HR
Analytics and Tracking
Widgets
WPML Multilingual
Font Awesome
Wordpress Plugins
Google Font API
Sitelinks Search Box
CookieYes for WordPress
Elementor
reCAPTCHA
Google Tag Manager
RankMath
Gravatar Profiles
Sticky Side Buttons
JetTabs
Stop User Enumeration
Ultimate Addons for Elementor
US Privacy User Signal Mechanism
CrUX Dataset
WP Statistics
Search and Filter